Eravacyclin (antibiotic of last resort: complicated intra-abdominal infections (cIAI)



  • Active Sustance: Eravacyclin
  • Name: Xerava®
  • Therapeutic area: Complicated intra-abdominal infections (cIAI)
  • Pharmaceutical company: PAION Deutschland GmbH


Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023


Comparative therapy:

  • No comparative therapy due to status as antibiotic of last resort